Biohaven Ltd (BHVN)
$41.21
+0.97
(+2.41%)▲
Market is closed - opens 7 PM, 29 Jul 2024
Performance
- $40.76$41.75$41.21
1.09%
Downside
Day's Volatility :2.37%
Upside
1.29%
- $16.45$62.21$41.21
60.08%
Downside
52 Weeks Volatility :73.56%
Upside
33.76%
Returns
| Period | Biohaven Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | 3.26% | 0.0% |
6 Months | -10.36% | 0.0% |
1 Year | 69.08% | 0.0% |
3 Years | -67.11% | -20.2% |
Highlights
Market Capitalization | 3.4B |
Book Value | $3.69 |
Earnings Per Share (EPS) | -6.9 |
Wall Street Target Price | 58.22 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -65.27% |
Return On Equity TTM | -133.69% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -534.8M |
Diluted Eps TTM | -6.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -7.26 |
EPS Estimate Next Year | -6.63 |
EPS Estimate Current Quarter | -1.57 |
EPS Estimate Next Quarter | -1.67 |
Analyst Recommendation
Buy
94%Buy
5%Hold
0
0%Sell
Based on 17 Wall street analysts offering stock ratings for Biohaven Ltd(by analysts ranked 0 to 5 stars)
Based on 17 analyst
- Current
- 1M Ago
- 3M Ago
Buy
16
16
14
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 41.28%
Current $41.21
Target $58.22
Technicals Summary
Sell
Neutral
Buy
Biohaven Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Biohaven Ltd | 14.91% | -10.36% | 69.08% | -67.11% | -9.88% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Biohaven Ltd | NA | NA | NA | -7.26 | -1.34 | -0.65 | NA | 3.69 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Biohaven Ltd | Buy | $3.4B | -9.88% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Biohaven Ltd
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 253.6%
Institutional Holdings
Vanguard Group Inc
7.15%Stifel Financial Corp
7.05%BlackRock Inc
6.48%HHG PLC
6.47%Suvretta Capital Management, LLC
4.53%T. Rowe Price Associates, Inc.
3.79%
Corporate Announcements
Biohaven Ltd Earnings
Biohaven Ltd’s price-to-earnings ratio stands at None
Read More
Company Information
Organization | Biohaven Ltd |
Employees | 239 |
CEO | Dr. Vladimir Coric M.D. |
Industry | Health Technology |
